Pdr5p is the yeast Saccharomyces cerevisiae ATPbinding cassette transporter conferring resistance to several unrelated drugs. Its high overproduction in Pdr1p transcription factor mutants allows us to study the molecular mechanism of multidrug transport and substrate specificity. We have developed new in vivo and in vitro assays of Pdr5p-mediated drug transport. We show that in spite of little sequence homology, and inverted topology in respect to that of mammalian P-glycoproteins, Pdr5p shares with them common substrates. Pdr5p extrudes rhodamines 6G and 123, from intact yeast cells in an energy-dependent manner. Plasma membrane preparations from a Pdr5p-overproducing strain exhibit ATP hydrolysis-dependent, osmotically sensitive rhodamine 6G fluorescence quenching. The quenching is competitively inhibited by micromolar concentrations of many anticancer drugs, such as vinblastine, vincristine, taxol, and verapamil, and of ionophoric peptides as well as steroids. In contrast, other anticancer drugs, like colchicine and some multidrug resistance modifiers, such as quinidine, exert noncompetitive inhibition. Our experimental system opens new possibilities for the analysis of structure-function relationship of multidrug transporter substrates and inhibitors.
The growth of yeast cell shows little sensitivity to most of the anticancer agents (1) , and it is not known whether any of the yeast ABC 1 proteins exhibits the broad, yet limited multidrug transport specificity similar to that of the P-glycoproteins of the MDR type, which in mammalian cells are responsible for many failures in cancer chemotherapy (2) (3) (4) .
To approach the intriguing problem of MDR transporter substrate specificity, we have taken advantage of the high abundance of the ABC transporter Pdr5p in plasma membranes isolated from Saccharomyces cerevisiae pdr1 or pdr3 transcription factor mutants (5) (6) (7) (8) (9) . Pdr5p shares limited amino acid sequence homology with mammalian P-glycoproteins (5, 10 -12) and has an inverted predicted topology of the two nucleotide binding folds relative to the two transmembrane domains. Similar structural organization is found in other yeast ABC proteins constituting a new distinct family of yeast open reading frames sharing close homology with PDR5 (13, 14) , including Snq2p which is also involved in multidrug resistance (11, 15) . Pdr5p has oligomycin-and vanadate-sensitive ATPase activity (6) . Inactivation of PDR5 by insertion (16) or deletion (10, 11) is not lethal to cells unexposed to drugs, does not affect their growth rate, mating, or sporulation, but results in a drug-hypersensitive phenotype. Overproduction of Pdr5p confers resistance to cycloheximide and several unrelated compounds, but resistance to anticancer drugs or ionophores was not tested so far (10, 11, 16, 17) .
In this study, we show that Pdr5p shares with mammalian P-glycoproteins a series of common substrates and inhibitors, which were kinetically characterized in a new in vitro Pdr5p drug transport assay.
EXPERIMENTAL PROCEDURES
Chemicals-Rhodamine 6G and sodium orthovanadate were from British Drug Chemicals, oligomycin from Janssen Chimica, 2 deoxy-Dglucose, progesterone, vinblastine, vincristine, taxol, tamoxifen, verapamil, puromycin, nifedipine, colchicine, yohimbine, quinidine, ␤-estradiol, gramicidin D, nigericin, monensin, ATP disodium salt (A-3377), GTP, UTP, and sodium deoxycholate were from Sigma, ATP␥S tetralithium salt, CTP, ADP, chloramphenicol, Triton X-100, and n-octyl glucoside were from Boehringer Mannheim, valinomycin, FCCP, and CCCP were from Fluka, S13 was a kind gift from Dr. P. Haman (Monsanto Co., St. Louis, MO), SF6847 was from Sumitomo Chemical Co. Ltd. (Osaka, Japan). Deoxycorticosterone was kindly provided by Dr. T. Wright. All other reagents were of analytical grade.
Yeast Strains-The following S. cerevisiae strains were used in this study: US50-18C (MAT␣, PDR 1-3, ura 3, his-1) (18), US50-D5 (US50-18C disrupted by pdr5-⌬3::URA3) (19) ) (C. Fairhead), FYMKU-1/1 (FY1679-28C disrupted by pdr5-⌬1::hisGURA3hisG) (this study), FYMKD-2/1 (diploid from cross between FYMKU-1/1 and FY1679-1D) (this study), FYMK-1/1 (FY1679-28C disrupted by pdr5-⌬1::hisG) (this study). FY1679-28C and FY1679-1D are segregants from a cross between FY23 and FY73 (20) . The PDR5 gene disruption was performed as described previously (7) except that the disrupted allele was verified by polymerase chain reaction amplification using the PDR5 wild type (GCATACGCAGGACCAC-GAGGAA, GCGAATCATTTGGCGGAAGTAGC) and deleted allele (AAGCAGGCGGCAGAAGAAGTAACA) specific primers used together in one reaction. The monogenic character of the disruption was verified by tetrad analysis. The URA3 gene was removed by 5-fluoro-orotic acid treatment (21) of appropriate transformants.
Plasmids-The KpnI fragment was removed from the previously described, Yep24-based pDR3-3 plasmid (16), yielding pMKR3-3. The KpnI-BamHI fragment containing the entire PDR5 gene and its promoter was obtained by partial digestion of pMKR3-3 and cloned into the KpnI-BamHI sites in the polylinker of pRS315 vector (22) partially digested with KpnI and BamHI, yielding pMK315-5. Yeast transformation was carried by the lithium acetate procedure (23) .
In Vivo Drug Sensitivity Assays-Cells grown on YPG medium, pH 6.8, were poured in top agar (seeded with 10 5 cells/ml) onto YPG plates (pH 6.8) of uniform thickness supplemented with 2% ethanol. Alternatively, the minimal YNB medium with 2% glycerol, 2% ethanol was used. Five l of drug ethanol solution was spotted onto a Whatman paper disc lying on the top agar. The following amounts (in nanomoles) of drugs were applied: rhodamine 6G, 104; rhodamine 123, 263; oligomycin, 1.26; gramicidin D, 20 g (about 9.7 nmol); CCCP, 100; FCCP, 25; valinomycin, 20; nigericin, 80; monensin, 100; ionophore A23187, 33; trifluoperazine, 210; tamoxifen, 116; daunomycin, 71; doxorubicin, 100; vinblastine, 75; vincristine, 11; verapamil, 307; taxol, 12; progesterone, 706; ␤-estradiol, 306; deoxycorticosterone, 862; puromycin, 92; nifedipine, 35; quinidine, 25; yohimbine, 284. Plates were incubated at 30°C until clear growth inhibition zones were visible. Ethanol alone did not affect growth. For each drug at least three reproducible measurements were done.
Rhodamine Transport in Intact Cells-Equal amounts of US50-18C and US50-D5 cells or of FY1679-28C and FYMK-1/1 (1 mg of total protein) from exponentially growing cultures (in the same medium as used for membrane preparations) were collected by centrifugation, washed 4 times with water, resuspended in 400 l of 50 mM HepesNaOH, pH 7.0, 5 mM 2 deoxy-D-glucose, 5 M rhodamine 6G or 123, and incubated for 2 h at room temperature. A 50-l aliquot of this cell suspension (125 g of total protein) was quickly spun down, washed twice with 50 mM Hepes-NaOH, pH 7.0, resuspended in 2 ml of the same buffer at room temperature, and placed in the stirred fluorimeter cuvette. Rhodamine efflux was started by the addition of 1 mM glucose. Cells were removed by quick centrifugation 7 min after glucose addition, and rhodamine fluorescence was measured in the resulting supernatant using an SLM Aminco 48000 S spectrofluorimeter. For rhodamine 6G, the excitation wavelength was 529 nm (slit 4) and the emission wavelength 553 nm (slit 8). For rhodamine 123, these wavelengths were, respectively, 505 nm (slit 4) and 534 nm (slit 8). The excitation and emission spectra of rhodamine 6G were recorded at 2 nm excitation and emission slit widths.
Determination of Intracellular ATP Levels-The CLS ATP bioluminescence assay (Boehringer Mannheim) was used to measure the ATP content in cell extracts, prepared according to the LKB bioluminescence assay instructions. Briefly, cell suspensions (prepared as described above) were diluted 50 times in boiling 0.1 M Tris-EDTA buffer (pH 7.75) and heated for 1 min. The resulting cell extracts were used for ATP determination in the integrating photometer 3000 of the SAI Technology Co.
Determination of Cell Viability-Cell viability was determined by counting colonies after plating on solid media and by the methylene blue exclusion method (24) .
Preparation of Plasma Membranes-Cells were grown in 10% glucose, 2% yeast extract (Difco), pH 4.5, and harvested in the exponential phase of growth. After washing and disruption in a Braun MSK cell homogenizer in 10 mM Tris-NaOH (pH 10.5), 0.25 M saccharose, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, unbroken cells, and cell debris were removed by low-speed centrifugation (2 ϫ 1500 ϫ g, 1 ϫ 4300 ϫ g). The resulting supernatants were centrifuged for 40 min at 20,200 ϫ g. Pellets were resuspended in 10 mM Tris-acetic acid, pH 7.5, 1 mM EDTA, and mitochondrial membranes were removed by acetic acid precipitation at pH 5.2 and pelleting by 2.5-min centrifugation at 7700 ϫ g, as described before (25) . The resulting supernatants were centrifuged for 36 min at 27,000 ϫ g. Each pellet, highly enriched in plasma membranes, was resuspended in 50 mM Hepes-NaOH, pH 7.0, frozen in liquid nitrogen, and stored at Ϫ70°C. The quality of the membranes was determined by 7% SDS-polyacrylamide gel electrophoresis, according to Laemmli (26) , and by ATPase activity measurements, as described by Dufour et al. (25) .
Fluorescence Measurements in Plasma Membrane Fractions-Membranes (30 g of protein) were resuspended in 2 ml of 50 mM HepesNaOH, pH 7.0, 5 mM MgCl 2 , 20 to 600 nM rhodamine 6G or 123, at 35°C. The reaction was started by addition of 5 mM ATP-NaOH, pH 7.0. Other parameters for fluorescence measurements were as described above for whole cells. Rhodamine 6G was used for inhibition kinetics measurements. Inhibitors were added as ethanol solutions. The ethanol concentration never exceeded 1%, and this solvent did not cause any measurable disturbances. The kinetic analysis of rhodamine 6G fluorescence quenching inhibitors was performed using the GraFit program (27) , assuming the model developed for P-glycoproteins by Michelson and Slate (28) . Trypsin digestion of plasma membrane fractions was carried out for 30 min in 50 mM Hepes-NaOH, pH 7.5, with 250 g/ml trypsin (1 g of trypsin/mg protein).
Protein Content Determination-The method of Lowry et al. (29) was used to determine the protein concentration, using bovine serum albumin as standard.
RESULTS
In Vivo Drug Sensitivity Assays-We have compared drug sensitivity of the pdr 1-3, mutant US50-18C, overproducing Pdr5p and the otherwise isogenic PDR5-deleted US50-D5 strains by agar diffusion assay. The former strain proved more resistant to growth inhibition by the fluorescent dyes rhodamine 6G, rhodamine 123, daunorubicin, and doxorubicin ( Fig.  1 ). These dyes are well-known substrates of mammalian Pglycoproteins, the latter two used in chemotherapy. We further found that Pdr5p confers resistance to growth inhibition by the anticancer drug tamoxifen and also by the MDR modifier trifluoperazine ( Fig. 1) . Other anticancer drugs, such as vinblastine, vincristine, taxol, verapamil, colchicine, MDR modifiers, such as puromycin, nifedipine, and also gramicidin D were not toxic to our yeast strains under the conditions used. The effect of oligomycin and of the protonophores FCCP and CCCP was not appreciably modified by Pdr5p. In contrast, the Ca 2ϩ ionophore A23187, and the ionophoric peptides monensin and nigericin were less toxic in the Pdr5p-overproducing than in the PDR5-deleted strain (Fig. 1) . Deletion of PDR5 increases also sensitivity to progesterone and deoxycorticosterone in contrast to ␤-estradiol which was not toxic (Fig. 1) . The case of valinomycin is more curious. Initially, identical growth inhibition zones were observed for the PDR5-overexpressing and -deleted strains. Upon further incubation, however, the inhibition zone disappeared in the case of the PDR5-deleted strain, but remained unchanged in the case of the overexpressing strain (Fig. 1) .
That the phenotypes are related to Pdr5p was confirmed by complementation of PDR5 deletion in the FYMK-1/1 strain FIG. 1. Ability of Pdr5p to mediate resistance to growth inhibition by fluorescent dyes, anticancer drugs, ionophores, and steroids. Plates containing YPG, pH 6.8, were seeded with cells of US50-18C or US50-D5 strains (except for deoxycorticosterone where FY1679-28C and FYMK-1/1 were used, and monensin where JG365-5C transformed either with Yep24 or pMKR3-3 were compared on minimal YNB medium), were made and analyzed as described under "Experimental Procedures."
with PDR5 borne on a centromeric plasmid and by cosegregation of rhodamine 6G hypersensitivity with PDR5 deletion (data not shown).
Extrusion of Rhodamine from Whole Cells-Rhodamines 6G and 123 are taken up by yeast cells and are commonly used to stain mitochondria (30) . We found the dyes to accumulate much more abundantly in the strain with the disrupted PDR5 gene, as evidenced by fluorescence microscopy, by visual observations of red colonies on plates containing rhodamine 6G, and by the red color of sedimented cell pellets after addition of rhodamine to liquid cultures (data not shown). Prolonged incubation of the cells in the presence of 2-deoxy-D-glucose (a glycolysis inhibitor) and rhodamine 6G (a mitochondrial ATPsynthase inhibitor) resulted in marked depletion of the intracellular ATP pool from 10 to 1 nmol of ATP/mg of cell proteins and in an almost equal loading of PDR5-overexpressing and PDR5-deleted cells with the dye, as addition of equal amounts of preloaded cells produced fluorescence signals of similar intensity (Fig. 2A) . The survival rate was similar for both strains after this incubation, as observed by vital staining and cell plating. The active Pdr5p-mediated extrusion of rhodamine 6G from intact cells was measured indirectly by monitoring glucose-stimulated fluorescence dequenching in de-energized, dye-preloaded cells ( Fig. 2A) and by directly measuring the fluorescence of extruded rhodamine in the assay buffer (Fig. 2B) . Addition of the energy source (glucose) caused the intracellular ATP level to rapidly increase up to 8 nmol of ATP/mg of protein in both strains. This was accompanied by rapid dequenching of rhodamine 6G fluorescence in the case of the Pdr5p-expressing cells but not in the case of the otherwise isogenic PDR5 disruptant ( Fig. 2A) . A parallel increase in rhodamine 6G fluorescence was observed in the external buffer after incubation of Pdr5p-expressing cells with glucose, as compared to controls where either Pdr5p or glucose was absent (Fig. 2B) . The excitation and emission spectra of rhodamine 6G observed before cell loading and after extrusion were indistinguishable (data not shown). FY1679-28C was also found to extrude rhodamine 6G at a higher rate than FYMK-1/1 (data not shown). Pdr5p-producing cells were found to extrude rhodamine 123 at a higher rate than PDR5 disruptants (data not shown). These results, together with the in vivo drug sensitivity results, identify Pdr5p as an efficient cell detoxification system, which can be inhibited by depletion of the intracellular ATP pool.
Quenching of Rhodamine 6G Fluorescence by Pdr5p-containing Plasma Membrane Preparations-Further characterization of Pdr5p activity was done with a plasma membrane-enriched fraction containing the transporter in high amount, as shown in Fig. 3 . Rapid quenching of rhodamine 6G fluorescence by Pdr5p-containing membranes occurred in the presence of Mg 2ϩ and ATP. This quenching was not observed when membranes from the isogenic PDR5 disruptant were used (Fig. 4) , although they appeared to be of the same quality, as revealed by similar SDS-polyacrylamide gel electrophoresis profiles (Fig. 3) and similar H ϩ -ATPase activity (data not shown). The reaction leading to rhodamine 6G fluorescence quenching was inhibited by nanomolar concentrations of oligomycin and micromolar concentrations of vanadate, these being known inhibitors of Pdr5p ATPase activity (6) . The reaction was also inhibited by a wide variety of mammalian MDR P-glycoprotein substrates, including the anticancer drugs vinblastine, vincristine, verapamil, and taxol at micromolar concentrations. When these inhibitors were added after rhodamine 6G quenching had reached a steady state, dequenching of fluorescence was observed as shown in Fig. 4 for oligomycin. Oligomycin at this concentration did not affect the rhodamine 6G fluorescence in the absence of Pdr5p. The rate of dequenching was proportional to the inhibitor concentration. When the inhibitor was added together with ATP before the start of the reaction, quenching occurred at a decreased rate, inversely proportional to the inhibitor concentration, as shown for tamoxifen in Fig. 5 . The nonhydrolyzable ATP analogue ATP␥S (31) could not substitute for ATP and was inhibitory in the presence of ATP, suggesting that hydrolysis of ATP is required to energize the reaction. Furthermore, rhodamine 6G fluorescence quenching was fully relieved by addition of detergent at low concentrations, such as 1.45 mM octyl glucoside, 0.1 mM sodium deoxycholate, or 0.005% Triton X-100. This shows that the dye was neither degraded nor modified. The process responsible for fluorescence quenching was not inhibited by 10 mM sodium azide, 100 mM potassium nitrate, or by protonophores such as 10 M CCCP, 10 M FCCP, 1 M S13, 1 M SF6847, added either before addition of ATP or after the steady state was reached. Quenching of rhodamine 6G fluorescence was completely abolished by a 30-min preincubation of the membranes with trypsin. Rhodamine 6G and rhodamine 123 had similar responses (data not shown).
Characterization of Rhodamine 6G Fluorescence Quenching Reaction-Modification of extravesicular osmolarity was achieved by preincubation of membranes with different amounts of sucrose in the assay buffer for 60 min at room temperature as described previously by Horio et al. (32) . Then the assay was performed at the same concentration of sucrose as that of preincubated membrane suspension. Fig. 6A shows that the Pdr5p-mediated, MgATP-dependent rhodamine 6G quenching reaction is osmotically sensitive. Its optimal temperature is 35°C (Fig. 6B) . The rhodamine 6G quenching reaction shows narrow optimum at pH 7 ( Fig. 6C) and shows a clear preference for MgATP as energy source (Fig. 6D ) with no activity observed without magnesium and with MgADP.
Characterization of Rhodamine 6G Fluorescence Quenching Inhibitors-The rate of rhodamine 6G fluorescence quenching in Pdr5p-enriched plasma membrane fractions reached a plateau value at rhodamine 6G concentrations above 400 nM (Fig.  7) . Michaelis-Menten kinetics revealed an apparent K m of Pdr5p for rhodamine 6G of 144 nM. Each tested inhibitor of rhodamine 6G fluorescence quenching was kinetically characterized. Some inhibitors displayed competitive, others noncompetitive inhibition (Fig. 7, A and B) . These inhibitors did not affect the rhodamine 6G fluorescence in the absence of Pdr5p. For each tested inhibitor, we determined the I 50 concentration at the rhodamine 6G concentration of 146 nM, as shown for tamoxifen in Fig. 5 . The results are summarized in Table I . DISCUSSION Using our newly developed assays based on in vitro rhodamine 6G fluorescence measurements and in vivo drug sensitivity, we show that in spite of little sequence homology to the mammalian P-glycoproteins and inverted topology, the yeast A, osmotic sensitivity of Pdr5p-mediated, MgATPdependent rhodamine 6G quenching. Membranes were preincubated for 60 min at room temperature in the assay buffer containing 0 -1 M sucrose, and then the assay was performed at the same sucrose concentration as described under "Experimental Procedures." B, temperature dependence of rhodamine 6G quenching reaction. C, determination of pH optimum of rhodamine 6G quenching reaction. To detect any indirect effects of buffers on the activity, the pH range of each buffer overlapped with the range of the next one. Buffers used were MesNaOH (pH 5.5-6.5), Mops-NaOH (pH 6.5-7), Hepes-NaOH (pH 7-8), Taps-NaOH (pH 8 -9) . D, dependence of rhodamine 6G quenching reaction on energy source. The solutions of triphosphonucleosides adjusted to pH 7 were added to 5 mM final concentration. multidrug transporter Pdr5p shares with them common substrates and inhibitors. The in vitro assay allowed us to kinetically characterize 22 inhibitors of the Pdr5p-mediated fluorescence quenching of rhodamine 6G.
We first identified, on the basis of in vivo toxicity assays performed on PDR5-deleted and -expressing strains, toxic compounds likely to be transported by Pdr5p such as the fluorescent dyes rhodamine 6G and rhodamine 123, the anticancer drugs daunorubicin, doxorubicin, tamoxifen, the chemosensitizer trifluoperazine, the ionophores nigericin, monensin, and A23187, and the steroid hormones progesterone and deoxycorticosterone. The fact that other anticancer drugs such as vinblastine or colchicine did not prove toxic to our yeast strains is not surprising, since others have made similar observations (1).
Furthermore, we observed Pdr5p-and energy-dependent extrusion of rhodamine 6G and rhodamine 123 from intact yeast cells, This confirms that these dyes, known substrates of mammalian MDR P-glycoproteins (33, 34) , are indeed transported by yeast Pdr5p. By vital staining and cell plating, we ruled out the possibility that the decreased rate of rhodamine 6G and 123 efflux from PDR5-deleted cells might be caused by decreased survival occurring during loading with the dye (data not shown). Moreover, addition of glucose to de-energized cells caused the ATP level to increase similarly in PDR5-expressing and PDR5-deleted strains. As expected for an ABC transporter energized by ATP hydrolysis, we found that depletion of the intracellular ATP pool inhibits transport of rhodamine 6G and rhodamine 123.
To confirm and characterize the drug-transporting activity of Pdr5p, we conducted further fluorescence quenching experiments on plasma membrane preparations. Preparations from the overexpressing strain can quench rhodamine 6G fluorescence in the presence of Mg 2ϩ and ATP. Similar preparations from the PDR5-deleted strain lack this ability. Quenching is abolished by protease treatment. This, together with our in vivo experiments, leaves no doubt that Pdr5p is responsible for the observed fluorescence quenching.
The observed quenching cannot be due to chemical modification of the fluorescent dye: addition of detergents completely restores the initial fluorescence intensity, and the rhodamine 6G excitation and emission spectra recorded before and after extrusion from whole cells, or before and after fluorescence quenching by membrane preparations, are indistinguishable (data not shown). The possible involvement in rhodamine 6G fluorescence quenching of proton motive force or of one of its components is unlikely, as shown by the lack of inhibition by protonophores, sodium azide (an inhibitor of mitochondrial ATPase), and by nitrate (an inhibitor of vacuolar ATPase and a membrane-permeating, ⌬-collapsing anion). Likewise, drug transport by the mouse MDR1 and MDR3 P-glycoproteins expressed in yeast secretory vesicles has been found not to be influenced by the proton motive force (35) .
Several lines of evidence suggest that MDR transporters can recognize their substrates in the cytoplasmic leaflet of the bilayer (36) and may function as flippases (37) . The ability of isolated membrane fractions to quench rhodamine 6G or 123 fluorescence provided they contain Pdr5p might be explained by modification of the distribution of the dye within the lipid bilayer although accumulation by inside-out plasma membrane vesicles cannot be excluded. This latter possibility would for example be consistent with the osmosensitivity of our assay and with the fact that rhodamine 6G forms at higher concentrations nonfluorescent dimers and trimers, which quench the monomer fluorescence (38) . We do not wish to take a position between these two possibilities.
Interestingly, the low I 50 values recorded for vanadate and oligomycin in our in vitro rhodamine 6G fluorescence quenching assay are strikingly similar to those observed for inhibition of Pdr5p nucleoside triphosphatase activity (6) . Micromolar concentrations of vanadate can also effectively inhibit the ATPase activity of mammalian P-glycoproteins (39) . As previously reported (6, 19) , we have confirmed that in our samples the plasma membrane bound Pdr5p hydrolyses UTP, CTP, GTP, and ITP at rates comparable with ATP with a broad pH optimum. However, the in vitro rhodamine transport has a narrow pH optimum and is energized by ATP. The difference in the pH sensitivity between ATPase activity and rhodamine 6G fluorescence quenching might be connected with the protonation state of the dye. The difference in nucleoside triphosphate specificity, however, sheds new light on the poorly understood mechanism of coupling ATP hydrolysis to drug transport by ABC transporters, since it indicates that although UTP and other triphosphonucleosides can be effectively hydrolyzed by Pdr5p, only the interaction of the nucleotide binding site with ATP produces proper energy transduction required for drug translocation.
The kinetic characterization of Pdr5p rhodamine 6G quenching inhibitors is consistent with the in vivo drug sensitivity assay results, showing that compounds whose toxicity is reduced by Pdr5p are competitive inhibitors of rhodamine transport including chloramphenicol, previously reported to be substrate of Pdr5p (40) . There is one exception, however, Pdr5p clearly mediates trifluoperazine resistance which appears to be a noncompetitive inhibitor of rhodamine 6G transport. It is possible that trifluoperazine is a transported substrate recognized at a site different from that of rhodamine 6G. Indeed, alterations of drug resistance profiles, particularly segregation of vinblastine resistance from daunomycin and colchicine resistance, have been observed in mutant P-glycoproteins (41) (42) (43) . This, together with the observations of Tamai and Safa (44) that azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein and observations of Ferry and co-workers (45, 46) , that the vinca alkaloid binding site is allosterically coupled to binding sites for dihydropyridines and taxanes, might reflect the presence of different drugbinding sites on P-glycoproteins for different classes of transported substrates. In this perspective it is interesting to note that colchicine noncompetitively inhibits Pdr5p-mediated rhodamine 6G fluorescence quenching in yeast plasma membranes whereas the vinca alkaloids vinblastine and vincristine were competitive inhibitors. Alternatively, in vitro trifluoperazine might bind to the ATP binding site of Pdr5p, as is the case for sarcoplasmic calcium ATPase (47) . In vivo, such an interaction could be prevented by direct extrusion of the compound from the membrane, before it reaches the nucleotide binding sites.
Another important aspect of our work is that Pdr5p mediates resistance to steroid hormones such as progesterone and deoxycorticosterone. The hypersensitivity to both compounds after deletion of PDR5 was observed in several strains bearing either the PDR1 wild type or pdr1-3 mutant allele. Although sensitivity to progesterone and deoxycorticosterone is influenced by the genetic background, the resistance was restored by transformation of PDR5 deleted strain by PDR5 on centromeric plasmid (data not shown). This and the fact that both hormones are potent competitive inhibitors of Pdr5p-mediated rhodamine 6G transport shows their direct interaction with Pdr5p and strongly suggests that they are indeed transported substrates of the pump. This adds new aspects to the observations made by Kralli et al. (12) that Pdr5p does not modify the accumulation in intact cells of progesterone and deoxycorticosterone, but affects accumulation of dexamethasone and triamcinolone acetonide. This conclusion was based on indirect measurements of hormone-inducible reporter gene activity, which was expressed differently in PDR5 wild type and a pdr5 mutant. Our data support the view that they used a mutant of altered substrate specificity. Another possibility is that the assay used by Kralli et al. (12) fails to detect differences clearly seen in the drug sensitivity assay.
Fluorescence-based assays of transport activity offer several advantages over the use of radiolabeled substrates (48) , commonly employed in the study of MDR transporters. Although two in vitro fluorescence-based assays of P-glycoprotein activity were reported to date (49, 50) , they lacked the sensitivity required for kinetic characterization of inhibitors. Our rhodamine 6G quenching assay is the first to our knowledge which allows for a detailed kinetic characterization of drug transport inhibitors by an MDR transporter. This has important consequences as its speed and simplicity allows rapid accumulation of data for precise characterization of the drug-transporter interactions and rational molecular modeling-based design of novel MDR reversing agents. Due to the capability of scaling up to microplate formats, in conjunction with molecular modeling techniques, our assay may become a powerful tool in the endless fight against ever outbreaking drug-resistant pathogens.
